Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Subjects Wtih Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Brief Summary: The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.


Options:
A: Change From Baseline in A1C at Week 26 (Excluding Rescue Approach) (Baseline and Week 26); Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (Up to Week 106); Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (Up to Week 104)
B: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions (Baseline through End of Study (up to 7.5 years)); Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions (Baseline through End of Study (up to 7.5 years))
C: Change in HbA1c From Baseline to Week 52 (Day 1 (Baseline) and Week 52)
D: Change in baseline HbA1c after 52 weeks

Answer: D